Please login to the form below

Not currently logged in
Email:
Password:

Astellas files patent suit against Sandoz

Astellas Pharma has filed a lawsuit against generics manufacturer Sandoz relating to a version of Astellas' organ transplantation drug, Prograf, which Sandoz plans to market in Canada

Astellas Pharma has filed a lawsuit against Sandoz, the generic division of Novartis, relating to a version of Astellas' Prograf (tacrolimus hydrate) that Sandoz plans to market in Canada.

The suit, which was filed in the Federal Court of Canada, contains an order prohibiting marketing approval from the Canadian Minister of Health for Sandoz's generic tacrolimus hydrate before the expiration of Astellas' patent for the therapy.

Prograf is currently approved in Canada and elsewhere as an immunosuppressant following organ transplantation.

Sandoz previously launched a generic version of Prograf in the US August 2009.

14th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics